Carola Susanne Koenig

Dr. Carola Susanne Koenig

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2022 in Sustainability
Verified
Journal Article
Open access
PDF file
MBMorgan Breen
Morgan Breen
Abiy S. KebedeAbiy S. Kebede
Abiy S. Kebede
Carola Susanne KoenigCarola Susanne Koenig
Carola Susanne Koenig
Climate change and continued urban development in flood-prone areas exacerbate flood risks. Flood Risk Management authorities often turn to structural protection measures to minimise losses. However, these measures often lead to infrastructural lock-ins with potential unintended consequences as increased safety can induce increased development, ultimately leading to higher losses in the event of failures of the structural safe-guards in place. This process has been referred to as the Safe Development Paradox: a cross-cutting science-policy-practice challenge that requires a systematic understanding in the context of climate change and the United Nations Sustainable Development Goals. Yet, there are no comprehensive review studies, to date, that summarize the state of knowledge of the Safe Development Paradox. This paper provides the first evidence base through a critical review of the state-of-the-art and quantitative analysis of the peer-reviewed English-language literature since 2000, highlighting key knowledge gaps and issues hindering progress in addressing the Safe Development Paradox. It was identified that current research is compounded by a lack of consistent terminology, limited geographic distribution of case studies, and skewed emphasis on fluvial flooding. The review ends with potential directions across the science, policy, and practice domains for increasing knowledge and tackling the Safe Development Paradox.

1 March 2001 in Medical Engineering & Physics
Verified
Journal Article
Closed access
Carola Susanne KoenigCarola Susanne Koenig
Carola Susanne Koenig
CCC. Clark
C. Clark
To provide a reliable tool for predicting the flow in a clinical sac-type ventricular assist device (VAD), a simplified model VAD was developed prior to this study for the purpose of experimental validation of computer simulations of the time-varying flow on a moving grid. At selected locations in the flow field, flow patterns, vortex core trajectories and velocities were compared between the numerical and physical models during one full pumping cycle. The computer simulations showed qualitatively very good agreement with the experiment. Quantitatively, the agreement was less favourable. In order to investigate flow mixing and to evaluate fluid residence times in the model VAD a new tool has been developed: the numerical simulations were extended by injecting a scalar into the flow domain. These simulations allow investigation of the flow mixing qualitatively by visualisation and quantification of fluid residence times. Experimental assessment of the numerical results using dye injection proved to be favourable. The numerical results have been extended to include some prediction of pressure which have been compared with experimental measurements.

1 January 2024 in The World Journal of Men's Health
Verified
Journal Article
Open access
GHGeoffrey Hackett
Geoffrey Hackett
AMAmar Mann
Amar Mann
AHAhmad Haider
Ahmad Haider
Karim Sultan HaiderKarim Sultan Haider
Karim Sultan Haider
PDPieter Desnerck
Pieter Desnerck
SRSudarshan Ramachandran
Sudarshan Ramachandran
While testosterone therapy can improve the various pathologies associated with adult-onset testosterone deficiency (TD), Summary of Product Characteristics (SPC) of five testosterone preparations caution that treatment may be associated with hypertension. This paper evaluates the impact of testosterone undecanoate (TU) on blood pressure (BP) in men with adult-onset TD. Of 737 men with adult-onset TD in an on-going, observational, prospective, cumulative registry, we studied changes in BP using non-parametric sign-rank tests at final assessment and fixed time points. We used multiple regression analysis to establish factors (baseline BP, age, change/baseline waist circumference [WC] and hematocrit [HCT] and follow-up) potentially associated with BP change in men on TU. TU was associated with significant reductions in systolic, diastolic BP and pulse pressure, regardless of antihypertensive therapy (at baseline or during follow-up), larger reductions were seen with concurrent antihypertensive therapy. In men never on antihypertensive agents, median changes (interquartile range [IQR]) in systolic BP, diastolic BP and pulse pressure were -12.5 (-19.0, -8.0), -8.0 (-14.0, -3.0), and -6.0 (-10.0, -1.0) mmHg, respectively at final assessment, with only baseline BP values inversely associated with these changes (HCT and WC were not significantly associated). In men not on TU, systolic BP, diastolic BP, and pulse pressure significantly increased. In the TU treated men only 1 of the 152 men (not on antihypertensive agents at baseline) were started on antihypertensives during follow-up. In contrast 33 of the 202 men on antihypertensives (at baseline or follow-up) had the antihypertensive agent discontinued by the end of the follow-up. TU was associated with lowering of BP during follow-up irrespective of antihypertensive therapy, with greater reductions in men with higher baseline BP. In the context of SPC warnings, our long-term data provide reassurance on the effect of TU on BP.

1 June 2007 in Journal of Chromatography A
Verified
Journal Article
Closed access
Carola Susanne KoenigCarola Susanne Koenig
Carola Susanne Koenig
ISI.A. Sutherland
I.A. Sutherland

12 March 2021 in Proceedings of the Institution of Mechanical Engineers, Part H: Journal of Engineering in Medicine
Verified
Journal Article
Open access
PDF file
Carola Susanne KoenigCarola Susanne Koenig
Carola Susanne Koenig
MAMark Atherton
Mark Atherton
MCMarco Cavazzuti
Marco Cavazzuti
CGCorinna Gomm
Corinna Gomm
SRSudarshan Ramachandran
Sudarshan Ramachandran
Cardiovascular disease (CVD) is the highest cause of death globally with more people dying annually from it than from any other cause. CVD is associated with modifiable risk factors (dyslipidaemia, hypertension and diabetes) and treating each of these factors lowers the risk of CVD. It is impossible to estimate the benefit of risk factor modification in the individual patient and extrapolating data from multiple trials is difficult. It would be useful to have a marker of risk that accurately estimates real time risk by measuring blood flow factors associated with the pathogenesis of atheroma. The aim of this preliminary study was to validate a low-cost measurement technique for obtaining blood flow velocity profiles and assess whether any of the measured and calculated factors, based on computational fluid dynamics (CFD) simulation, known to be associated with atheroma was associated with coronary heart disease (CHD), thus establishing its feasibility and acceptability as a clinical tool and suggesting areas for future research. Our study identified (i) that mean peak systolic (PS) velocity being associated with CHD; individuals without CHD: mean (SD) = 62.8 (16.1) cm/s, with CHD: mean (SD) = 53.6 (17.3) cm/s, p = 0.042; and (ii) that low-cost, portable ultrasound, which is routinely available in general practice, is a suitable assessment tool.

12 April 2018 in Journal of Engineering and Science in Medical Diagnostics and Therapy
Verified
Journal Article
Open access
PDF file
SRSudarshan Ramachandran
Sudarshan Ramachandran
Carola Susanne KoenigCarola Susanne Koenig
Carola Susanne Koenig
GHGeoffrey Hackett
Geoffrey Hackett
MLMark Livingston
Mark Livingston
RSRichard C. Strange
Richard C. Strange
The use of reference ranges is well established in medical practice and research. Classically, a range would be derived from the local healthy population and matched in age, gender, and other characteristics to the patients under investigation. However, recruiting suitable controls is problematic and the derivation of the range by excluding 2.5% at each end of the distribution results in 5% of the values being arbitrarily discarded. Thus, the traditional reference range is derived using statistical and not clinical principles. While these considerations are recognized by clinicians, it is often not realized that the application of whole population derived reference ranges to complex pathologies that comprise patient subgroups may be problematic. Such subgroups may be identified by phenotypes including genetic etiology, variations in exposure to a causative agent, and tumor site. In this review, we provide examples of how subgroups can be identified in diverse pathologies and how better management can be achieved using evidence-based action limits rather than reference ranges. We give examples from our clinical experience of problems arising from using the wrong reference ranges for the clinical situation. Identifying subgroups will often enable clinicians to derive specific action limits for treatment that will lead to customized management and researchers a route into the study of complex pathologies.